Traws Pharma Q1 net loss $7.1M; secures up to $60M PIPE financing

Traws Pharma, Inc.

Net loss of $7.1M ($0.53/share) vs net income of $21.5M in Q1 2025; revenue $0.
R&D expense $4.9M (up 96% YoY) on antiviral trial milestones; cash $3.1M at March 31.
Up to $60M private placement closed April 15 with $10M upfront, expected to fund ops into Q1 2027.
TXM influenza prophylaxis advancing to human challenge trial in Q2 2026; FDA clinical hold unresolved.
New hantavirus program initiated; no approved treatments exist for this disease.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.